Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

McGill University

$120,000.00

Defining the role of c-KIT positive luminal progenitor cells in breast cancer heterogeneity and endocrine therapy resistance

EF 2025-26

Résumé
Breast cancer is the most common cancer among women and remains a major cause of death despite significant advances in early detection and treatment. One of the greatest challenges is its heterogeneity: tumors can differ in cell types, behaviour, and response to therapy, which limits the effectiveness of current treatments and contributes to recurrence. Luminal breast cancers, defined by the presence of hormone receptors such as estrogen (ER) and progesterone (PR), represent the majority of cases and are treated with endocrine therapies such as tamoxifen. However, many patients relapse, indicating that not all cancer cells are equally sensitive to these therapies. Recent studies show that a specific cell type, luminal progenitor cells, can give rise to both hormone-sensitive and hormone-insensitive breast cancers depending on genetic and signaling changes. Using advanced single-cell analyses, our team has identified a consistent population of luminal progenitor cells that lack hormone receptors but express a protein called c-KIT, which regulates cell growth, survival, and plasticity. We hypothesize that these c-KIT positive cells are a source of tumor diversity and survival after treatment. This project will investigate whether c-KIT drives the emergence of different breast cancer subtypes and promotes resistance to endocrine therapy. Using an established breast cancer model that closely mimics human disease (Py230), we will reduce or increase c-KIT levels to determine its role in shaping tumor identity and in survival after tamoxifen treatment. By analyzing the fate of these cells, including their capacity to persist and recur, we aim to clarify whether c-KIT identifies or actively drives therapy-resistant populations. This work will generate new knowledge on how breast cancer heterogeneity and treatment resistance arise, with the potential to identify a predictive biomarker.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
560240
Name
Martel Alexandrine
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Defining the role of c-KIT positive luminal progenitor cells in breast cancer heterogeneity and endocrine therapy resistance
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Breast Cancer; C-Kit Receptor; Endocrine Therapy Resistance; Subtype Plasticity; Tumor Heterogeneity
Abstract
Breast cancer is the most common cancer among women and remains a major cause of death despite significant advances in early detection and treatment. One of the greatest challenges is its heterogeneity: tumors can differ in cell types, behaviour, and response to therapy, which limits the effectiveness of current treatments and contributes to recurrence. Luminal breast cancers, defined by the presence of hormone receptors such as estrogen (ER) and progesterone (PR), represent the majority of cases and are treated with endocrine therapies such as tamoxifen. However, many patients relapse, indicating that not all cancer cells are equally sensitive to these therapies. Recent studies show that a specific cell type, luminal progenitor cells, can give rise to both hormone-sensitive and hormone-insensitive breast cancers depending on genetic and signaling changes. Using advanced single-cell analyses, our team has identified a consistent population of luminal progenitor cells that lack hormone receptors but express a protein called c-KIT, which regulates cell growth, survival, and plasticity. We hypothesize that these c-KIT positive cells are a source of tumor diversity and survival after treatment. This project will investigate whether c-KIT drives the emergence of different breast cancer subtypes and promotes resistance to endocrine therapy. Using an established breast cancer model that closely mimics human disease (Py230), we will reduce or increase c-KIT levels to determine its role in shaping tumor identity and in survival after tamoxifen treatment. By analyzing the fate of these cells, including their capacity to persist and recur, we aim to clarify whether c-KIT identifies or actively drives therapy-resistant populations. This work will generate new knowledge on how breast cancer heterogeneity and treatment resistance arise, with the potential to identify a predictive biomarker.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Martel, Alexandrine
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~